Editorial: Antiviral innate immune sensing, regulation, and viral immune evasion.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Antiviral innate immunity in myocarditis: mechanisms and emerging therapeutics.Experimental & molecular medicine · 2026
   Review
2. TRIM47 catalyzes MAVS SUMOylation to safeguard chronic viral infections and tissue inflammation.Cell communication and signaling : CCS · 2026
   Article
3. TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways.Mucosal immunology · 2025
   Article
4. Tug of war: innate immunity and herpes simplex keratitis.Frontiers in immunology · 2025
   Review

Corrections and comments

• Commented on by
  Editorial: Community series in antiviral innate immune sensing, regulation, and viral immune evasion: volume II.2023

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as